+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Radiation change versus recurrent astrocytoma: diagnostic utility of the proliferation index?

Radiation change versus recurrent astrocytoma: diagnostic utility of the proliferation index?

Journal of Neuro-Oncology 41(1): 55-63

Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1% and the LI of recurrent neoplasm was > 3%, with pertinent exceptions. We discuss our findings and their possible interpretation.

(PDF same-day service: $19.90)

Accession: 047159272

Download citation: RISBibTeXText

PMID: 10222423

DOI: 10.1023/a:1006112228001

Related references

The axial diagnostic and sensitive-to-change for depression index: diagnostic utility and use in studies of therapeutic evaluation. Actas Espanolas de Psiquiatria 38(1): 42-49, 2011

Recurrent astrocytoma versus primary astrocytoma: a comparative study of morphological changes of 32 cases. Hua Xi Yi Ke Da Xue Xue Bao 25(1): 91-93, 1994

Villous hypertrophy versus choroid plexus papilloma: A case report demonstrating a diagnostic role for the proliferation index. Pediatric Neurosurgery 39(2): 91-96, July, 2003

Pilomyxoid astrocytoma with high proliferation index. Journal of Pediatric Neurosciences 8(3): 243-246, 2014

MIB-1 proliferation index predicts survival among patients with low grade astrocytoma. Journal of Histochemistry & Cytochemistry 44(7): 791, 1996

MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. Journal of Neuropathology and Experimental Neurology 57(10): 931-936, 1998

Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. Journal of Neuro-Oncology 82(3): 305-311, 2006

Diagnostic Utility of WISC-IV General Abilities Index and Cognitive Proficiency Index Difference Scores Among Children With ADHD. Journal of Applied School Psychology 28(2): 133-154, 2012

Electromagnetic radiation at 835 MHz changes the morphology and inhibits proliferation of a human astrocytoma cell line. Bioelectrochemistry & Bioenergetics. 43(1): 13-18, 1997

Complete regression of a recurrent astrocytoma grade iii by combined treatment with radiation therapy and razoxane. Aktuelle Neurologie 14(5): 168-170, 1987

Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer 117(17): 4070-4079, 2011

Combined proliferation and aneusomy index strongly predict survival of young patient with astrocytoma grade 2 Implications for treatment strategy. Neurology 58(7 Supplement 3): A17-A18, April 9, 2002

The diagnostic utility index. Medical Education (Oxford) 13(6): 425-427, 1979

Utility of P16 expression and Ki-67 proliferation index in ASCUS and ASC-H pap tests. Diagnostic Cytopathology 42(7): 576-581, 2015